Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Zacks Investment Research on MSN21h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateNovo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...
Australia is considering a World Trade Organisation challenge against US President Donald Trump’s steel and aluminium tariffs ...
Rocket Lab will launch a private radar imaging satellite to orbit tonight (March 14), and you can watch the action live ...
The head of Poland’s space agency was fired over a bungled response to SpaceX debris falling over Polish territory.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback